BAY 73-6691

• Catalog No.: B3561
• CAS Number: 794568-92-6
• M. F.: C15H12ClF3N4O
• M. W.: 356.7301896
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one
• IUPAC Traditional name: 1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
• Synonyms: 1-(2-Chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one

DATABASE IDS

• CAS Number: 794568-92-6
• MDL Number: MFCD08705319
• PubChem SID: 24724419

PROPERTIES

• Empirical Formula (Hill Notation): C15H12ClF3N4O
• Purity: ≥98% (HPLC)
• Apperance: off-white powder
• Solubility: DMSO: >20 mg/mL
• GHS Signal Word: Danger
• GHS Hazard statements: H300-H315-H319-H335-H413
• European Hazard Symbols: Toxic (T)
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
• GHS Precautionary statements: P261-P264-P301 + P310-P305 + P351 + P338
• RID/ADR: UN 2811 6.1/PG 3
• Risk Statements: 25-36/37/38
• Safety Statements: 26-45
• Storage Temperature: 2-8°C
• Hazard Class: 6.1
• UN Number: 2811
• Packing Group: 3
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
BAY 73-6691 was characterized in vitro as the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment of Alzheimer′s disease. This compound selectively inhibits human (IC50 = 55 nM) and murine (IC50 = 100 nM) PDE9 activity in vitro and shows only moderate activity against other cyclic nucleotide-specific phosphodiesterases. BAY 73-6691 alone did not significantly increase basal cGMP levels. The PDE9 inhibitor significantly potentiated the cGMP signals generated by sGC activating compounds such as BAY 58-2667 or 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine (BAY 41-2272) and induced leftward shifts of the corresponding concentration-response curves. The newly generated PDE9 reporter cell line show that BAY 73-6691 is able to efficiently penetrate cells and to inhibit intracellular PDE9 activity.†

Description (简体中文)

Biochem/physiol Actions
BAY 73-6691 was characterized in vitro as the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment of Alzheimer′s disease. This compound selectively inhibits human (IC50 = 55 nM) and murine (IC50 = 100 nM) PDE9 activity in vitro and shows only moderate activity against other cyclic nucleotide-specific phosphodiesterases. BAY 73-6691 alone did not significantly increase basal cGMP levels. The PDE9 inhibitor significantly potentiated the cGMP signals generated by sGC activating compounds such as BAY 58-2667 or 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine (BAY 41-2272) and induced leftward shifts of the corresponding concentration-response curves. The newly generated PDE9 reporter cell line show that BAY 73-6691 is able to efficiently penetrate cells and to inhibit intracellular PDE9 activity.†